NEW YORK (GenomeWeb News) – Ariosa Diagnostics has filed a regulatory document with the US Securities and Exchange Commission for an initial public offering.

In its preliminary prospectus filed with the SEC on Monday, the San Jose, Calif.-based developer of non-invasive prenatal tests said it intends to offer $69 million in a proposed maximum aggregate offering price. It has not priced its shares yet or said how many share it plans to offer.

Ariosa said that it plans to list its shares on the Nasdaq Global Market under ticker symbol "AROS."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.